Gardasil DTC driving force behind Merck expense increase

Share this article:
Gardasil DTC was the chief factor behind a 21% increase in Merck marketing and administrative expenses for the fourth quarter of 2006, followed by consumer promotion of Zostavax and spending on the Januvia launch, said CEO Dick Clark in a Q4 earnings report.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Pharmaceutical

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.